Gilead (GILD) Lags Other Biotechs Following HCV Data From Regulus (RGLS)
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $130.23 -3.42%
Rating Summary:
37 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 9 | New: 17
Rating Summary:
37 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 9 | New: 17
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) shares declined Wednesday, falling over 1.5% despite gains in the Nasdaq biotech index, which was up 2.75%.
Softness in shares of Gilead follows positive data from Regulus Therapeutics (NASDAQ: RGLS). Earlier Regulus announced encouraging interim results from its ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection.
In a research note, Jefferies analyst Brian Abrahams said RG-101 may be disruptive in HCV but the threat to Gilead was "unclear."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Gilead Sciences (GILD) to Buy
- Netflix eyes Letterboxd acquisition, Variety reports, citing Puck
- Trump: Cease Fire Is Over
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
